Chr. Hansen -- a global bioscience company, is entering a partnership with oral immunotherapy developer Prota Therapeutics for an innovative peanut allergy treatment.
The ambitious scientific project begins with Chr. Hansen's LGG probiotic strain and the researchers hope to enhance the formula by "bringing Prota Therapeutics' drug candidate, as one of two active pharmaceutical ingredients alongside LGG." The expectation is that the peanut allergy treatment will reach phase three in the clinical trial -- which is identified as "one of the first to involve a live microorganism." Chr. Hansen and Prota Therapeutics expect this trial to last about three years.
Although the investigation is focused on determining if probiotic treatment can have a soothing effect on peanut allergies, the researchers will potentially look into exploring its merits in collaboration with other foods.
Photo Credits: Shutterstock
Key Themes Behind This Trend
- Probiotic Peanut Allergy Treatments
- The use of probiotics in treating peanut allergies offers a potential breakthrough in allergy treatment.
- Combining Probiotics with Active Pharmaceutical Ingredients
- The combination of probiotics with active pharmaceutical ingredients presents a disruptive innovation opportunity for the pharmaceutical industry.
- Live Microorganisms in Clinical Trials
- The exploration of live microorganisms in clinical trials is a trending area of research and could pave the way for new treatment options for various conditions.
Where This Applies
- Pharmaceuticals
- Pharmaceutical companies could develop new treatments by combining probiotics with active pharmaceutical ingredients to treat various conditions.
- Food and Beverage
- The use of probiotics in treating peanut allergies could offer a new approach to food allergy management and could lead to greater innovation in the food and beverage industry.
- Health and Wellness
- The use of probiotics in treating allergies has the potential to revolutionize the health and wellness industry with new treatment options.
